Predictors of successful long-term blood pressure control in type 2 diabetic patients: Data from the Swedish National Diabetes Register (NDR)

Journal of Hypertension

Volumn 23, Issue 12, 2005, Pages 2305-2311

  Nilsson, Peter M ^a   Cederholm, Jan ^b   Gudbjörnsdottir, Soffia ^c   Eliasson, Björn ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Diabetes; Hypertension; Microalbuminuria; Obesity; Register

Indexed keywords

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR RISK; DATA ANALYSIS; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REGISTER; REGISTRATION; RISK ASSESSMENT; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 27944478620     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000188733.60345.78     Document Type: Article

References (30)

1. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316:823-828.
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.
3. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762.
4. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004-1010.
5. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
6. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24:1601-1610.
7. Clark MJ Jr, Sterrett JJ, Carson DS. Diabetes guidelines: a summary and comparison of the recommendations of the American Diabetes Association, Veterans Health Administration, and American Association of Clinical Endocrinologists. Clin Ther 2000; 22:899-910.
8. Tenenbaum A, Fisman EZ, Boyko V, Goldbourt U, Graff E, Shemesh J, et al. Hypertension in diet versus pharmacologically treated diabetics: mortality over a 5-year follow-up. Hypertension 1999; 33:1002-1007.
9. Nilsson PM, Gudbjörnsdottir S, Eliasson B, Cederholm J, for the Steering Committee of the National Diabetes Register in Sweden. Hypertension in diabetes: trends in clinical control in repeated national surveys from Sweden 1996-99. J Hum Hypertens 2003; 17:37-44.
10. Gudbjörnsdottir S, Cederholm J, Nilsson PM, Eliasson B, for the Steering Committee of the Swedish National Diabetes Register. The National Diabetes Register (NDR) in Sweden: An implementation of the St. Vincent Declaration for quality improvement in diabetes care. Diabetes Care 2003; 26:1270-1276.
11. Eliasson B, Cederholm J, Nilsson PM, Gudbjörnsdottir S. A gap between guidelines and reality: Results from The Swedish National Diabetes Register 1996-2003. Diabet Med 2005; 22:1420-1426.
12. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291:335-342.
13. 1c and microalbuminuria than non-smokers: data from the Swedish National Diabetes Register. Diabetes Metab 2004; 30:261-268.
14. Cederholm J, Eliasson B, Nilsson PM, Weiss L, Gudbjörnsdottir S, for the Steering Committee of the Swedish National Diabetes Register. Microalbuminuria and risk factors in type 1 and type 2 diabetic patients. Diabetes Res Clin Pract 2005; 67:258-266.
15. 1c analyses in Sweden [in Swedish]. Diabetol News 2002; 4:8-12.
16. 1c in human blood and the national standardization schemes in the United States, Japan and Sweden: a method-comparison study. Clin Chem 2004; 50:166-174.
17. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-553.
18. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR, on behalf of the United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56) [multimedia adjunct]. Clin Sci (Lond) 2001; 101:671-679.
19. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Nel HA, Holman RR, for the UK Prospective Diabetes Study Group. UKPDS 60. Risk of stroke in Type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002; 33:1776-1781.
20. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990; 39:167-174.
21. Sung KC, Kim BJ, Kim BS, Kang JH, Lee MH, Park JR, et al. In normoglycemic Koreans, insulin resistance and adipocity are independently correlated with high blood pressure. Circ J 2004; 68:898-902.
22. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317:350-357.
23. Lind L, Lithell H, Pollare T. Is it hyperinsulinemia or insulin resistance that is related to hypertension and other metabolic cardiovascular risk factors? J Hypertens 1993; 11(Suppl):S11-S16.
24. Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 2003; 254:45-66.
25. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-259.
26. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
27. Wang TJ, Evans JC, Meigs JB, Rifai N, Fox CS, D'Agostino RB, et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005; 111:1370-1376.
28. Mancia BG, Pessina AC, Trimarco B, Grassi G, on behalf of the SILVIA (Studio Italiano sulla Valutazione della Ipertensione Arteriosa nel 2000) Study Group. Blood pressure control according to new guidelines targets in low- to high-risk hypertensives managed in specialist practice. J Hypertens 2004; 22:2387-2396.
29. Ginsberg HN. New perspectives on atherogenesis. Role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002; 106:2137-2142.
30. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986; 112:432-437.